The 7 most recent market catalysts affecting $SOPH, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Sophia Genetics, Raises Price Target to $14
HC Wainwright & Co. analyst Swayampakula Ramakanth maintained a 'Buy' rating on Sophia Genetics (SOPH) and raised the price target from $12 to $14. This action indicates a strength…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Sophia Genetics, Raises Price Target to $9
BTIG analyst Mark Massaro maintained a 'Buy' rating on Sophia Genetics (SOPH) and raised the price target from $8 to $9. This action indicates increased confidence from a prominent…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 85
SOPHiA GENETICS shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY26 sales guidance above analyst estimates.
This headline is a significant corporate catalyst for SOPHiA GENETICS. The combination of beating Q2 sales expectations and, more importantly, raising long-term guidance (FY26) abo…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 75
Sophia Genetics Raises FY2026 Sales Guidance from $92.000M-$94.000M to $94.000M-$96.000M vs $93.403M Est
Sophia Genetics (SOPH) has raised its FY2026 sales guidance, which is a significant positive development for the company. The new guidance range of $94.000M-$96.000M not only repre…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 75
SOPHiA GENETICS Announces Global Collaboration To Develop, Validate, And Deploy Two Companion Diagnostics Supporting Precision Oncology Therapies With AstraZeneca
SOPHiA GENETICS has entered a multi-year global collaboration with AstraZeneca to develop and commercialize two companion diagnostics (CDx) for precision oncology. This agreement i…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 75
Sophia Genetics shares are trading higher after HC Wainwright & Co. initiated coverage on the stock with a Buy rating and announced a $12 price target.
This headline represents a significant corporate catalyst for Sophia Genetics. Analyst initiations with 'Buy' ratings and ambitious price targets often act as strong signals to the…
Jul 20, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Initiates Coverage On Sophia Genetics with Buy Rating, Announces Price Target of $12
HC Wainwright & Co. has initiated coverage on Sophia Genetics (SOPH) with a 'Buy' rating and a $12 price target. This event is significant because new analyst coverage, especially …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.